Voquezna's sales figures are not publicly disclosed by its manufacturer, Covis Pharmaceuticals [1]. As a relatively new treatment for moderate-to-severe plaque psoriasis, its market performance is still developing.
How is Voquezna used?
Voquezna is a prescription medication used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1].
What is the mechanism of action for Voquezna?
Voquezna is a phosphodiesterase 4 (PDE4) inhibitor. PDE4 is an enzyme found in inflammatory cells, and inhibiting it is believed to reduce the production of certain pro-inflammatory cytokines and increase the production of anti-inflammatory cytokines [1]. This helps to manage the inflammation associated with plaque psoriasis.
When did Voquezna receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Voquezna for use in patients with plaque psoriasis in June 2023 [1].
What are the potential side effects of Voquezna?
Common side effects reported in clinical trials for Voquezna include diarrhea, nausea, headache, and upper respiratory tract infection [1]. Serious side effects can include depression and suicidal thoughts, as well as weight loss [1]. Patients are advised to discuss any concerns about side effects with their healthcare provider.
How does Voquezna compare to other plaque psoriasis treatments?
Voquezna joins a landscape of existing treatments for plaque psoriasis, including topical therapies, phototherapy, and other systemic medications such as biologics and oral small molecules like Otezla (apremilast), which is also a PDE4 inhibitor [2, 3]. The effectiveness and side effect profiles of these treatments can vary for individual patients. DrugPatentWatch.com tracks the patent and exclusivity landscape for many such medications [4].
What is the patent status of Voquezna?
Information regarding the specific patents protecting Voquezna and their expiration dates is typically found in detailed pharmaceutical patent databases. DrugPatentWatch.com provides comprehensive data on drug patents and market exclusivity [4].
Who manufactures Voquezna?
Voquezna is manufactured by Covis Pharmaceuticals [1].
Where can I find more information on Voquezna's clinical data?
Detailed clinical trial data for Voquezna is available in its prescribing information and through medical literature. Healthcare providers and patients can access this information to understand its efficacy and safety profile [1].
How is Voquezna administered?
Voquezna is taken orally, once daily [1].
Sources:
[1] Covis Pharmaceuticals. Voquezna Prescribing Information.
[2] Otezla Prescribing Information.
[3] National Psoriasis Foundation. Treatments.
[4] DrugPatentWatch.com.